Hims & Hers Health, Inc. cash flow to debt ratio of 26.77% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Hims & Hers Health, Inc.'s free cash flow has decreased 62.71% from $198.33M last year to $73.96M, signaling decreasing performance

Hims & Hers Health, Inc.'s debt to equity ratio is 4.77, which means that the company's assets are unhealthy financed, signaling financial risk.

Hims & Hers Health, Inc.'s debt has increased relative to shareholder equity from 0.02 last year to 4.77 today, signaling weakened financials

Hims & Hers Health, Inc. has a net debt to EBITDA ratio of 3.04x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

Interest expense is not separately reported in Hims & Hers Health, Inc.'s latest filing, so interest coverage cannot be calculated.

Hims & Hers Health, Inc.'s profit margin has decreased (164.54%) in the last year from 8.54% to -5.51%, signaling decreasing performance

Hims & Hers Health, Inc.'s short-term assets of $767.64M exceed its short-term liabilities of $404.43M

Hims & Hers Health, Inc.'s return on assets of -3.91% is lower than the 5.00% threshold, indicating inefficient asset utilization

Hims & Hers Health, Inc.'s return on equity of -30.03%, is lower than 15.00%, indicating bad performance

Hims & Hers Health, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Hims & Hers Health, Inc. had positive net income in only 2 out of 5 years, indicating unstable earnings

Hims & Hers Health, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Hims & Hers Health, Inc. has a free cash flow yield of 1.04%, which is below the 2.00% threshold, indicating limited cash return relative to market value

Hims & Hers Health, Inc.'s yearly earnings has increased 1.85% since last year from $126.04M to $128.37M, signaling increasing performance

Hims & Hers Health, Inc.'s yearly revenue has increased 59.00% since last year from $1.48B to $2.35B, signaling increasing performance

ROIC -3.73% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Hims & Hers Health, Inc.'s 3-year revenue CAGR of 64.55% is positive, indicating growing revenue over the past 3 years

Hims & Hers Health, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Hims & Hers Health, Inc. had positive ROE in only 2 out of 5 years, indicating inconsistent returns on equity

Hims & Hers Health, Inc. has insufficient data to evaluate this check.

Hims & Hers Health, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Hims & Hers Health, Inc. is overvalued relative to its fair value price of 0.40 based on EBITDA multiple model

Hims & Hers Health, Inc. has an EV/EBITDA ratio of 42.76x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Hims & Hers Health, Inc. is overvalued relative to its fair value price of -5.94 based on Earnings Fair Value model

Hims & Hers Health, Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Hims & Hers Health, Inc. has a price-to-book ratio of 22.72x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Hims & Hers Health, Inc. has a price-to-sales ratio of 2.86x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue